Indoco Remedies enters into distribution partnership with Clarity Pharma
Mumbai: Indoco Remedies Limited, a fully integrated, research
based pharma company has announced a strategic
collaboration between Indoco Remedies and Clarity Pharma, UK.
The company will launch around 20 products over
the next 18 months through Clarity Pharma, its distributor in the UK. The Company will
continue to supply all the products under existing B2B partnership to its clients.
the next 18 months through Clarity Pharma, its distributor in the UK. The Company will
continue to supply all the products under existing B2B partnership to its clients.
Aditi Panandikar, Managing Director, Indoco Remedies Ltd., commented, “This
collaboration with Clarity Pharma is a significant milestone for Indoco as this will further
strengthen our foothold in the UK pharma market. By combining Indoco’s robust portfolio of
high-quality, affordable pharmaceutical products with Clarity Pharma’s strong distribution
network and market expertise, we are poised to deliver innovative healthcare solutions to a
broader patient base.”
collaboration with Clarity Pharma is a significant milestone for Indoco as this will further
strengthen our foothold in the UK pharma market. By combining Indoco’s robust portfolio of
high-quality, affordable pharmaceutical products with Clarity Pharma’s strong distribution
network and market expertise, we are poised to deliver innovative healthcare solutions to a
broader patient base.”
Steve Soper, CEO of Clarity Pharma commented, ‘Today is the beginning of a truly exciting
journey between Indoco and Clarity and is the result of several years’ hard work in putting
this market access project together. The range of Indoco products is exciting and extensive
and will deliver significant savings to the market once launched, we look forward to a bright
future of collaboration, growth, and making a difference in the affordability of a wide range
of medicines’.
journey between Indoco and Clarity and is the result of several years’ hard work in putting
this market access project together. The range of Indoco products is exciting and extensive
and will deliver significant savings to the market once launched, we look forward to a bright
future of collaboration, growth, and making a difference in the affordability of a wide range
of medicines’.
Indoco is a fully integrated, research-oriented pharmaceutical company with a strong global
presence. The Company’s turnover is US$ 212 million. The Company has 11 manufacturing facilities, 7 for FDFs and 4 for APIs, supported by a state-of-the-art R&D Centre and a CRO facility. The facilities have been approved by most of the Regulatory Authorities including USFDA and UK-MHRA. Indoco develops and manufactures a wide range of pharmaceutical products for the Indian and international markets. It generates more than 106 million prescriptions annually from over 2,35,000 doctors belonging to various specialties. Indoco has 8 domestic marketing divisions a strong brand portfolio in various therapeutic segments including Gastro-intestinal, Respiratory, Anti-Infective, Stomatologicals, Ophthalmic, Nutritionals, Cardiovascular, Anti-Diabetics, Pain Management, Gynaecology etc.
presence. The Company’s turnover is US$ 212 million. The Company has 11 manufacturing facilities, 7 for FDFs and 4 for APIs, supported by a state-of-the-art R&D Centre and a CRO facility. The facilities have been approved by most of the Regulatory Authorities including USFDA and UK-MHRA. Indoco develops and manufactures a wide range of pharmaceutical products for the Indian and international markets. It generates more than 106 million prescriptions annually from over 2,35,000 doctors belonging to various specialties. Indoco has 8 domestic marketing divisions a strong brand portfolio in various therapeutic segments including Gastro-intestinal, Respiratory, Anti-Infective, Stomatologicals, Ophthalmic, Nutritionals, Cardiovascular, Anti-Diabetics, Pain Management, Gynaecology etc.
Facebook Comments
